

Dr Jack H. LADENSON **is the winner of the 2017 IFCC Distinguished Award for** **Contributions to Cardiovascular Diagnostics**

Milan, 28 April 2017 - The IFCC, the international leading organization in the field of Clinical Chemistry and Laboratory Medicine, is pleased to announce that **Dr Jack H. LADENSON** (Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, US), **is the winner of the 2017 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics, sponsored by HyTest**. This award honours an individual who has undertaken remarkable scientific work with cardiac markers or immunodiagnostic applications to improve cardiac disease diagnosis. It will be presented for the first time on occasion of the WorldLab Congress to be held in Durban in 2017. The IFCC is very pleased to acknowledge the support from HyTest in the recognition of scientists and educators with a distinguished career in this area.

Dr Ladenson is one of the researchers who helped bring the field of cardiovascular diagnostics to its current state, being instrumental in the development of diagnostic tests for myocardial infarction and other cardiac diseases. He developed the first monoclonal antibody for the quantification of CK-MB, which was used by almost all commercial CK-MB measurement procedures and was for many years the gold standard biomarker of myocardial infarction. He then went on to develop the first monoclonal antibody and immunoassay for quantifying Troponin I the current gold standard biomarker for myocardial infarction. He used this assay to prove the clinical importance of this biomarker for evaluating myocardial infarction. His Troponin I assay is used in several current FDA-approved assays.

Prof. Howard MORRIS, IFCC President-Elect and Chair, IFCC Awards Committee, said: "We are delighted to select **Dr Ladenson** as the 2017 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics recipient. His lifelong commitment to cardiovascular diagnostics through the development and validation of two key diagnostic tests for cardiovascular disease, namely CK-MB and cardiac troponin I, makes him an outstanding candidate for this award".

The 2017 IFCC Awardees are a witness of the contribution that IFCC gives to advancement of excellence in laboratory medicine for better healthcare worldwide. **Dr Ladenson** along with seven other IFCC Distinguished Award winners will be formally announced on Sunday 22nd October at the Opening Ceremony of the 23rd IFCC International Congress in Clinical Chemistry and Laboratory Medicine being held in Durban (South Africa) from 22st to 25th October 2017.

- end -

ABOUT IFCC

IFCC is the leading organization in the field of Clinical Chemistry and Laboratory Medicine worldwide. Through leadership and innovation in science and education, IFCC strives to enhance the scientific level and the quality of diagnosis and therapy for patients throughout the world. IFCC builds on the professionalism of its members to provide quality services to patients. IFCC is a Federation of 90 Full Member and 12 Affiliate member Societies of Clinical Chemistry and Laboratory Medicine representing more than 45.000 individual clinical chemists, laboratory scientists, and laboratory physicians and 48 Corporate Members covering the major areas of clinical laboratory developments.

For further details please contact: ifcc@ifcc.org.

ABOUT HyTest



Established in 1994, HyTest Ltd is a recognized producer of high-quality monoclonal antibodies and antigens for the diagnostic industry all around the world.

Building on a strong scientific basis, HyTest has become the global market leader in supplying certain reagents. With several products appointed as the best in the world. HyTest is a company with an excellent track record and is known for its uncompromising quality. Continuous investments in R&D ensure a constant flow of new, even better reagents for the customers. That's why most of the major diagnostic companies rely on HyTest's ability to supply the best reagents in the world. For more information visit: www.hytest.fi